
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline
Aarhus, Denmark, 11 July 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with severe neuromuscular diseases, today announces that it has hired three senior recruits to its management team to support its growing business and pipeline. Peter Kasten will begin as Vice President Finance in August, Cecilia Sparr Eskilsson as Vice President Project Management in August and Maja B. Nielsen as People & Culture Director in September.
Mr. Kasten has over 15 years of experience in financial operations. Most recently, he was at Danske Fragtmænd, a Danish transport and logistics business, for several years in different roles of rising seniority. Prior roles include as Manager, Advisory Services – Finance and Performance Management at EY (Ernst & Young) and, notably, 10 years in roles of increasing responsibility at Novo Nordisk, where his work included projects to establish research centres in the USA and Denmark relating to its obesity programs.
Dr. Eskilsson is an accomplished scientist with over 20 years’ expertise in pharmaceutical drug development at AstraZeneca and LEO Pharma, with extensive experience in leading global scientific and strategic projects through clinical development phases. She will build out the company’s project management organization.
Ms. Nielsen has been leading global Human Resources departments in various companies since 2007. She joins from ENABL, the renewable wind energy company, where she is VP of Global HR. She brings extensive experience in the development of HR strategies, performance processes and training and development policies with companies employing personnel across the globe.
Thomas Holm Pedersen, Co-founder and Chief Executive Officer of NMD Pharma, said:“Over the last year our business has grown and matured, and we will have three Phase 2 clinical trials initiated and recruiting in North America and Europe by the end of the year. These high-quality additions to our management team, together with some other key senior hires, bring a wealth of knowledge and experience to propel our business forward with timely execution of a growing pipeline and portfolio of projects. I look forward to working with Peter, Cecilia, and Maja.”
NMD Pharma is developing first-in-class, muscle-targeted small molecule inhibitor of the skeletal muscle specific ClC-1 chloride ion channel. Three open Investigational New Drug (IND) studies are progressing for lead development candidate NMD670, including a Phase 2 clinical study in spinal muscular atrophy (SMA) (NCT05794139), a Phase 2b study in generalized myasthenia gravis (gMG) (NCT06414954) and IND clearance to begin a Phase 2 study in Charcot-Marie-Tooth disease (CMT) (NCT06482437).
Patients interested in learning more about any of these trials are encouraged to read the information on currently active investigational sites which can be found on each on clinicaltrials.gov webpage referenced above or to contact a member of our medical team via email at contact@nmdpharma.com.
-END-
Contacts
NMD Pharma A/S
Daniel Brennan, SVP Corporate and Commercial Strategy
E-mail: contact@nmdpharma.com
ICR Consilium
Mary-Jane Elliott / Ashley Tapp / Lindsey Neville
E-mail: NMDPharma@consilium-comms.com
Tel: +44 (0)20 3709 5700
About NMD Pharma
NMD Pharma A/S is a clinical-stage biotech company developing a first-in-class platform of small molecule therapies selectively and directly targeting the skeletal muscle chloride ion channel (ClC-1) for the treatment of severe neuromuscular disorders. The Company was founded on more than 15 years of muscle physiology research with a focus on regulation of skeletal muscle excitability under physical activity. NMD Pharma has built a world-leading muscle electrophysiology platform leveraging the in-depth know-how of muscle physiology and muscular disorders, small molecule modulators, enabling technologies and tools as well as in vivo pharmacology models for discovering and developing proprietary modulators of neuromuscular function. The Company has built significant clinical and development expertise as its programmes have progressed through the clinic. NMD Pharma has raised ~€155 million from investors including Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, Roche Venture Fund, and Jeito Capital. Find out more about us online at http://www.nmdpharma.com.
About NMD670
NMD670 is a first-in-class, muscle-targeted small molecule inhibitor of the skeletal muscle specific ClC-1 chloride ion channel. It is NMD Pharma’s lead development program which is being evaluated in 3 Phase 2 clinical studies in neuromuscular diseases. NMD Pharma has demonstrated that CIC-1 inhibition enhances skeletal muscle activation and improves skeletal muscle function. This novel treatment approach has demonstrated compelling preclinical data and clinical results in myasthenia gravis, spinal muscular atrophy, Charcot-Marie-Tooth disease and a range of other neuromuscular disorders. NMD670 has also been granted orphan-drug designation by the U.S. FDA for treatment of generalised myasthenia gravis (gMG). In March 2024 a comprehensive data package on NMD670 was published in the peer-reviewed journal Science Translational Medicine which generated significant interest including a research highlight commentary review in Nature Reviews Drug Discovery.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release
Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a
DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release
Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68
Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release
Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.
Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release
AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us
Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release
VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin